Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing LossBenzinga • 03/23/21
Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose RegimenBusiness Wire • 03/23/21
Do Options Traders Know Something About Frequency Therapeutics (FREQ) Stock We Don't?Zacks Investment Research • 03/22/21
Earnings Preview: Frequency Therapeutics, Inc. (FREQ) Q4 Earnings Expected to DeclineZacks Investment Research • 03/18/21
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322Business Wire • 02/22/21
Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product PlanningBusiness Wire • 02/08/21
Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing OfficerBusiness Wire • 01/19/21
Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/21
Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing LossBusiness Wire • 12/18/20
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial OfficerBusiness Wire • 12/01/20
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial ResultsBusiness Wire • 11/16/20
Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 ResultsSeeking Alpha • 11/09/20
Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a AnalysisBusiness Wire • 10/29/20
Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing LossBusiness Wire • 09/22/20
Frequency Therapeutics Has A Strong Scientific Rationale And An Upcoming Binary CatalystSeeking Alpha • 09/17/20
Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322Business Wire • 09/13/20
Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical MeetingsBusiness Wire • 09/08/20
Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial ResultsBusiness Wire • 08/12/20